

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**( 深圳市海普瑞藥業集團股份有限公司 )**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 9989)**

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Monday, August 29, 2022 for the purpose of, among other matters, considering and approving the interim results of the Group for the six months ended June 30, 2022 and its publication, the payment of an interim dividend, if any, and transacting any other business.

By order of the Board

**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**

**Li Li**

*Chairman*

Shenzhen, the PRC

August 15, 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*